Safia Rizvi

Dr. Rizvi brings over 20 years of experience in all aspects of Biopharma value chain, from drug discovery to commercialization. She Leverages science and business expertise to enhance pipeline, accelerate regulatory approval, optimize reimbursement, and creates value for biopharma. Over the 20 years, she closed deals worth a combined total of $12+ billion, managed P&L of > $1 billion, and launched 10 products in the US, EU, and Asia Pacific, each with different regulatory and market access environments.

Dr. Rizvi is also a founder Cila Therapeutics, a company developing inhaled therapeutics for respiratory rare diseases. While there, she translated scientific concepts into a robust pipeline of 5 programs and built a team of advisors with world class experts in pulmonary medicine, inhaled therapeutics and biopharma R&D. Dr. Rizvi currently serves as Chief Operating Officer at CaraVan Biologix Inc., a company developing a revolutionary platform technology for the treatment of solid cancer tumors and other human diseases.

Dr. Rizvi received her MBA in Health Care Management from the Wharton School of Business and holds a PhD in Chemistry with numerous authored articles in peer-reviewed scientific journals. She is an inventor of over 50 patent filings for therapeutic and therapeutic targets.